Overview

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of the study is that single doses of MK-1006 will be sufficiently safe and well tolerated, based on the assessment of clinical and laboratory evaluations and adverse experiences, in Japanese participants with T2DM.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.